| ¿µ¹® | immunological reaction | ÇÑ±Û | ¸é¿ª¹ÝÀÀ |
|---|---|---|---|
| ¼³¸í | »ýüÀÇ ¸ö ¾È¿¡¼ »ý±ä ¹°ÁúÀ̳ª ¸ö ¹Û¿¡¼ µé¾î¿Â ¹°ÁúÀÌ »ýü¿Í ´Ù¸¦ ¶§ ÀÚ±â ü³»ÀÇ ÅëÀϼº°ú °³Ã¼ÀÇ »ýÁ¸ À¯Áö ¹× Á¾ÀÇ Á¸¼ÓÀ» À§ÇÏ¿© ±× ¹°ÁúµéÀ» Á¦°ÅÇÏ´Â ÀÏ·ÃÀÇ »ýü ¹ÝÀÀ. ´Ù½Ã ¸»ÇØ B¼¼Æ÷¿¡ ÀÇÇÑ Ç×ü»ý»ê, T¼¼Æ÷¸¦ Áß½ÉÀ¸·Î ÇÏ´Â ¼¼Æ÷¼º ¸é¿ª, ¸é¿ª°ü¿ë, ¸é¿ª±â¾ï µîÀÇ »ýü ³» ¹ÝÀÀÀ» ¸»ÇÑ´Ù. Å«Æ÷½Ä¼¼Æ÷´Â Ç׿øÀ» ó¸®Çؼ ƯÀÌÀûÀÎ Ç׿ø°áÁ¤±â¸¦ °®´Â ºÐÀÚ·Î ¹Ù²ã, Ç׿ø°ú ÁÖ¿äÁ¶Á÷ ÀûÇÕÀ¯ÀüÀÚº¹ÇÕü¸¦ ¼¼Æ÷Ç¥¸é¿¡ Ç¥ÇöÇϸç, T¼¼Æ÷·Î Àü´ÞÇÑ´Ù. ÇÑÆí B¼¼Æ÷´Â Å«Æ÷½Ä¼¼Æ÷ ³»¿¡¼ ó¸®µÈ Ç׿øÀÇ °áÁ¤±â¸¦ ÀνÄÇÏ¿© ´ëÀÀÇϴ ƯÀÌÀûÇ×ü¸¦ »ý»êÇÏ¿© Ç׿øÀ» ó¸®ÇÑ´Ù. |
||
| ¿µ¹® | recognition, perception | ÇÑ±Û | ÀÎÁö, ÀνÄ, ÀçÀÎ½Ä |
|---|---|---|---|
| ¼³¸í | »ýü°¡ Àڱ⠶Ǵ Àڱ⿡°Ô ÀûÇÕÇÑ °ÍÀ¸·Î ºñÀڱ⸦ ½Äº°ÇÏ´Â °Í. »ýü°¡ ¾î¶°ÇÑ ÀÚ±ØÀ» ¼ö¿ëü µîÀ¸·Î ¼ö¿ëÇÏ¿© ½Äº°ÇÑ °á°ú ÀÏ¾î³ º¯È, ¹ÝÀÀ ¶Ç´Â Çൿ±îÁö¸¦ Æ÷ÇÔÇØ¼ ¸»ÇÏ´Â °æ¿ìµµ ÀÖ´Ù. Ç׿øÀÚ±ØÀ» ¹ÞÀº ¸é¿ª´ã´ç¼¼Æ÷¿¡ ÀϾ´Â º¯È¿Í °°Àº ¹°Áú¼öÁØÀÇ Çö»óÀ¸·ÎºÎÅÍ °íµîµ¿¹°¿¡¼ °³Ã¼ÀÇ ÀÎÁö µîÀÌ ÀÖ´Ù. ¶ÇÇÑ º¸´Ù °íÂ÷ÀÇ Ãß»óÀûÀÎ °³³äÀ¸·Î¼ °¨°¢¿¡ ÀÖ¾î¼ÀÇ ÀÎÁö³ª ÁßÃ߽ŰæÀÇ ´É·Â¿¡ °ü¿©ÇÏ´Â ÆÐÅÏÀÎ½Ä µîÀÌ ÀÖ´Ù. |
||
| IT | immunological test; immunotherapy; implantation test; individual therapy; information technology; in... |
|---|---|
| ARAM | antigen recognition activation motif |
| CEARP | Continuing Education Approval and Recognition Program |
| CERP | Continuing Education Recognition Program |
| CRD | carbohydrate-recognition domain; chronic renal disease; chronic respiratory disease; child restraint... |
| R.I.A. | radio-immunological assay |
|---|---|
| CRD | Carbohydrate recognition domain |
| FRT | FLP recognition target |
| MARE | Maf recognition element |
| ORC | Origin Recognition Complex |
| recognition factors | Factors which effect "recognition" of target antigens by polymorphonuclear leukocytes; apparently the Fc portion of antibody molecules and the activated third component of complement (C3), for both of which phagocytes have receptor sites. (05 Mar 2000) |
|---|---|
| recognition sequence | A nucleotide sequence --typically composed of 4, 6, or 8nucleotides -- that is recognised by a restriction endonuclease. Type II enzymes cut (and theircorresponding modification enzymes methylate) within or very near the recognition sequence. (09 Oct 1997) |
| recognition time | The interval between the application of a stimulus and the recognition of its nature. (05 Mar 2000) |
| pattern recognition | In information retrieval, machine-sensing or identification of visible patterns (shapes, forms, and configurations). (harrod's librarians' glossary, 7th ed) (12 Dec 1998) |
| pattern recognition, visual | Visually perceived characters, shapes, displays, or designs. (12 Dec 1998) |
| cell recognition | <cell biology> Interaction between cells that is possibly dependent upon specific adhesion. Since the mechanism is not entirely clear in most cases, the term should be used with caution. (26 Mar 1998) |
| signal recognition particle | A complex between a 7S RNA and six proteins. SRP binds to the nascent polypeptide chain of eukaryotic proteins with a signal sequence and halts further translation until the ribosome becomes associated with the rough endoplasmic reticulum. One of the SRP proteins (srp54) binds GTP and in association with 7SRNA and srp19 has GTPase activity. (18 Nov 1997) |
| signal recognition particle receptor | Receptor for the signal recognition particle (SRP) found in the membrane of the endoplasmic reticulum. Also called docking protein. Heterodimeric, both protomers having GTP binding capacity, though dissimilar binding sites. Not until the complex of SRP, ribosome, message and nascent polypeptide chain binds to the SRP receptor is the block to further chain elongation released and concurrently the SRP is released, leaving the ribosome attached to the endoplasmic reticulum membrane. Cotranslational transport of the polypeptide delivers it into the lumen of the ER. (18 Nov 1997) |
| dual recognition hypothesis | An outmoded hypothesis that is known to be incorrect now that the structure of the T-cell receptor is known. The proposal was that viral (and some chemical) antigens were recognised in association with histocompatibility antigens by separate receptors on the T-cell. The generation of cytotoxic T-cells was by association with Class I MHC antigens, of T helper cells by association with Class II MHC antigens. See: altered self hypothesis. (18 Nov 1997) |
| models, immunological | Theoretical representations that simulate the behaviour or activity of immune system, processes, or phenomena. They include the use of mathematical equations, computers, and other electrical equipment. (12 Dec 1998) |
| immunological | Pertaining to immunology. (18 Nov 1997) |
| immunological competence | <immunology> The bodys ability to develop an immune response to infection or disease. Immunocompetence is measured to see how well the body can fight off certain disease. Many cancer patients become immunocompromised, where their immune system is not as strong as a healthy person's. (16 Dec 1997) |
| immunological deficiency | Inabillity to mount a normal immune response. Immunodeficiency can be due to a genetic disease or acquired as in aids due to HIV. (12 Dec 1998) |
| immunological disease | <immunology> Any illness, such as an allergy, that is caused by the action of antibodies. (09 Oct 1997) |
| immunological enhancement | In immunology, the potentiating effect of specific antibody in establishing and in delaying rejection of a tumour allograft; aside from antibody, non-specific substances may also act to enhance immune response. Synonym: immunological enhancement. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|